Trial of Antibiotic Prophylaxis in Elective Laparoscopic Colorectal Surgery: Oral and Systemic Versus Systemic Antibiotics
This study has been completed.
Sponsor:
Japan Multinational Trial Organization
Information provided by (Responsible Party):
Hiroaki Hata, Japan Multinational Trial Organization
ClinicalTrials.gov Identifier:
NCT00508690
First received: July 27, 2007
Last updated: September 18, 2012
Last verified: September 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine optimal prophylactic antibiotics administration method in elective laparoscopic colorectal surgery.
| Condition | Intervention | Phase |
|---|---|---|
|
Colorectal Neoplasms |
Drug: cefmetazole Drug: kanamycin/metronidazole |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Randomized Controlled Trial of Antibiotic Prophylaxis in Elective Laparoscopic Colorectal Surgery: Oral and Systemic Versus Systemic Antibiotics |
Resource links provided by NLM:
Drug Information available for:
Kanamycin
Metronidazole
Metronidazole benzoate
Kanamycin sulfate
Metronidazole hydrochloride
U.S. FDA Resources
Further study details as provided by Japan Multinational Trial Organization:
Primary Outcome Measures:
- Incidence and classification of surgical site infection (SSI) [ Time Frame: Within the first 30 days after surgery ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Incidence of colitis, other infectious diseases and other postoperative complications. [ Time Frame: Within the first 30 days after surgery ] [ Designated as safety issue: No ]
| Enrollment: | 584 |
| Study Start Date: | September 2007 |
| Study Completion Date: | December 2011 |
| Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: IV
Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
|
Drug: cefmetazole
Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
|
|
Active Comparator: Oral/IV
2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
|
Drug: kanamycin/metronidazole
2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
|
Detailed Description:
The use of antibiotic prophylaxis in patients who undergo elective colorectal surgery is now accepted universally. But the rout of administration should be systematic, oral, or both is controversial. Furthermore, although many trails have been performed, no trial limited to laparoscopic surgery is performed. We compare 2 approaches - oral and systemic versus systemic antibiotic prophylaxis - in limited to elective laparoscopic colorectal surgery.
Eligibility| Ages Eligible for Study: | 20 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Colorectal tumor(cancer, adenoma and suspected cases) with planned elective laparoscopic colorectal resection
Exclusion Criteria:
- ECOG Performance Status >=2
- Age<20
- Any organ dysfunction
- Ileus
- Preoperative infectious disease
- Antibiotic administration before surgery
- Steroid administration before surgery
- Neo-adjuvant radiation and/or chemo therapy
- Severe diabetes mellitus
- Pregnancy/lactational woman
- Severe allergy
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00508690
Locations
| Japan | |
| Tenriyorozu Hospital | |
| Tenri, Nara, Japan, 6328552 | |
| National Hospital Organization, Kyoto Medical Center | |
| Kyoto, Japan, 612-8555 | |
| Kyoto Univercity Hospital | |
| Kyoto, Japan, 606-8507 | |
| Kyoto Katsura Hospital | |
| Kyoto, Japan, 6158256 | |
| Kitano Hospital | |
| Osaka, Japan, 5308480 | |
Sponsors and Collaborators
Japan Multinational Trial Organization
Investigators
| Principal Investigator: | Hiroaki Hata, MD | National Hospital Organization Kyoto Medical Center |
More Information
Additional Information:
No publications provided
| Responsible Party: | Hiroaki Hata, member, Japan Multinational Trial Organization |
| ClinicalTrials.gov Identifier: | NCT00508690 History of Changes |
| Other Study ID Numbers: | JMTO PREV07-01, UMIN000000776 |
| Study First Received: | July 27, 2007 |
| Last Updated: | September 18, 2012 |
| Health Authority: | Japan: Institutional Review Board |
Keywords provided by Japan Multinational Trial Organization:
|
Antibiotic Prophylaxis Colorectal Surgery Laparoscopy |
Additional relevant MeSH terms:
|
Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Anti-Bacterial Agents Cefmetazole |
Kanamycin Metronidazole Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Protein Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Radiation-Sensitizing Agents Physiological Effects of Drugs Antiprotozoal Agents Antiparasitic Agents |
ClinicalTrials.gov processed this record on May 21, 2013